Correction to: Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?

Marden, Emily; Ntai, Ioanna; Bass, Scott; Flühmann, Beat

Marden, Emily; Ntai, Ioanna; Bass, Scott; Flühmann, Beat.

Afiliação

Marden E; Food, Drug and Medical Device Regulatory Law, Sidley Austin LLP, Palo Alto, California, USA.
Ntai I; Non-Biological Complex Drugs, Vifor Pharma Ltd., Flughofstrasse 61, 8152, Opfikon, Switzerland.
Bass S; Global Life Sciences, Sidley Austin LLP, Washington, D.C., USA.
Flühmann B; Non-Biological Complex Drugs, Vifor Pharma Ltd., Flughofstrasse 61, 8152, Opfikon, Switzerland. beat.fluehmann@viforpharma.com.

AAPS J ; 20(6): 104, 2018 09 25.

Article em En | MEDLINE | ID: mdl-30255312

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article